viewParadigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals has success with PPS osteoarthritis treatment

Of 45 patients treated, 84.4% responded with a reduction in joint pain.

X-ray vision of knee joints
The comparative effects of PPS therapy against opioid treatments are promising

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has released promising information from trials of its injectable pentosan polysulfate sodium (PPS) treatment.

Of 45 patients treated, 84.4% responded with both a reduction in joint pain and an improvement in knee function.

Patients’ self-reported pain scores were reduced by 50% on average from baseline pain scores in 45 patients with knee osteoarthritis and concurrent bone marrow lesions.

In January, a European patent was granted for the treatment of bone marrow edema lesions with PPS.

READ: Paradigm Biopharmaceuticals granted European patent

Results represent improvement on opioid treatments

The patients were treated by their doctor with injectable PPS under the Therapeutic Goods Administration’s Special Access Scheme (SAS).

The 50% reduction in pain scores observed with PPS in knee osteoarthritis is significant in relative terms.

It demonstrates superiority over the independently reported 15% pain reduction scores for opioid treatments for chronic pain in osteoarthritis of the knee and hip.

Fits criteria of clinically meaningful pain reduction

The comparative effects of PPS therapy against opioid treatments implies that the data provides evidence of clinically meaningful improvements in chronic pain.

Clinically meaningful reduction of chronic pain has been defined to be between 25-30% pain reduction by an independent source.

These results precede the read-out from Paradigm’s phase IIb randomised, double-blind, placebo-controlled, multicentre, clinical trial, which is expected in the fourth quarter.

By that stage the phase IIb clinical trial data will be supplemented with an additional 150 patients.

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: 3.16 AUD

Market: ASX
Market Cap: $710.2 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...


2 min read